Hydrolysis of cefamandole nafate in dialysis patients.
The hydrolysis of cefamandole nafate was examined in vivo in five dialysis patients and five subjects with normal renal function. The plasma half-life of cefamandole was prolonged in the patients with renal failure compared with normal subjects (18.3 +/- 4.5 [standard deviation] versus 10.35 +/- 1.4 min, P less than 0.01). The pharmacokinetics of cefamandole nafate best fit two-compartment, open-model kinetics. We conclude that patients with severe renal failure are capable of hydrolyzing cefamandole nafate to cefamandole and formate at a rate sufficiently rapid so as not to allow an accumulation of cefamandole nafate. The difference in half-life may be related to urinary excretion of cefamandole nafate in normal individuals.
D000328:Adult; D000368:Aged; D002435:Cefamandole / Q000031:analogs & derivatives / Q000097:blood*; D002511:Cephalosporins / Q000097:blood*; D006207:Half-Life; D006801:Humans; D006868:Hydrolysis; D007676:Kidney Failure, Chronic / Q000097:blood*; D007700:Kinetics; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
D002511:Cephalosporins; D002435:Cefamandole